Pinnacle Bancorp Inc. Sells 445 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 7th, 2023

Pinnacle Bancorp Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,990 shares of the company’s stock after selling 445 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of Pinnacle Bancorp Inc.’s portfolio, making the stock its 14th largest holding. Pinnacle Bancorp Inc.’s holdings in Johnson & Johnson were worth $2,825,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Veracity Capital LLC raised its stake in Johnson & Johnson by 1.2% in the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares in the last quarter. Sandy Cove Advisors LLC grew its position in Johnson & Johnson by 1.6% during the third quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after acquiring an additional 60 shares during the last quarter. Paces Ferry Wealth Advisors LLC grew its position in Johnson & Johnson by 0.7% during the third quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after acquiring an additional 62 shares during the last quarter. Mason & Associates Inc grew its position in Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after acquiring an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC grew its position in Johnson & Johnson by 0.7% during the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock valued at $1,451,000 after acquiring an additional 62 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $165.15 on Friday. The stock has a fifty day moving average of $157.44 and a 200 day moving average of $167.03. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The firm has a market capitalization of $430.10 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 2.70 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.13 earnings per share. As a group, research analysts expect that Johnson & Johnson will post 10.5 earnings per share for the current year.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Piper Sandler reduced their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 1st. Guggenheim initiated coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price on the stock. Finally, UBS Group initiated coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.67.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.20% of the stock is owned by insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.